吗氯贝胺与丙咪嗪治疗重度抑郁症对照研究

A randomised controlled trial comparing meclobemide(Aurorix)and imipramine in the treatment of major depression

为确定吗氯贝胺（Ａｕｒｏｒｉｘ）抗抑郁疗效及耐受性，以丙咪嗪为对照，作随机对照研究。共纳入２０例重度抑郁病人（ＤＳＭ—Ⅲ—Ｒ），观察组和对照组各１０例。采用临床总体评定和量表（ＨＡＭＤ、ＣＧＡＥ和ＣＧＡＴ）评价疗效和耐受性。疗程６周。结果显示，两组疗效无显著差异。吗氯贝胺的耐受性显著优于丙咪嗪。两药均未见严重的不良反应。因此吗氯贝胺是一种安全、有效的新一代ＭＡＯＩ类抗抑郁剂。

Objective:To compare the efficacy of meclobemide and imipramine in the treatment of major depression. Method:20 patients with major depressive episode(DSM-Ⅲ-R) were randomised to receive either meclobemide or imipramine for six weeks.They were monitored with the Hamilton Rating Scale for Depression (HAMD),Clinical Global Assessment of Efficacy (CGAE) and clinical evaluation. Results:here was no significant difference in the response rate between the two treatment groups.Meclobemide was significantly better tolerated than imipramine.There was no serious adverse side effect for both medications. Discussion:Meclobemide is a useful and safe antidepressant.